Home Become a Member Contact Us WinPicks Software Scoresline Sports Forum

Forums   Register   Profile   Inbox   Address Book   Subscribe   My Forums   Search   FAQ   Login   Log Out
CVM $ CEL-Sci $ Next Hotstock on Watch $ https://investorshub.advfn.com/boards/bo   Logged in as: Guest
Users viewing this topic: none
  Printable Version
All Forums >> [Market Sectors] >> Healthcare and Pharmaceutical Stocks >> CVM $ CEL-Sci $ Next Hotstock on Watch $ https://investorshub.advfn.com/boards/bo Page: [1]
Login
Message << Older Topic   Newer Topic >>
CVM $ CEL-Sci $ Next Hotstock on Watch $ https://in... - 4/25/2017 2:33:54 PM   
Bullrider77

 

Posts: 413
Joined: 1/1/2010
Status: offline
CVW - NEXT HOT STOCK $

CEL-SCI Scientist Presents at the World Vaccine Congress
Print
Alert
Cel Sci (AMEX:CVM)
Historical Stock Chart

1 Month : From Mar 2017 to Apr 2017
Click Here for more Cel Sci Charts.

CEL-SCI Corporation (NYSE MKT: CVM) today announced that Dr. Daniel Zimmerman, its Senior Vice President of Research, Cellular Immunology, is presenting at the 17th Annual World Vaccine Congress held in Washington D.C. on April 12, 2017. The conference runs from April 10-12, 2017. The title of his presentation is “Unmet need for therapeutic vaccines for autoimmune conditions with emphasis on arthritis – and a look into the future.”

At the conference, Dr. Zimmerman is presenting data supporting a potentially novel approach to fighting the inflammation in the joints caused by rheumatoid arthritis. He introduced animal data that demonstrates that using CEL-SCI’s LEAPS CEL-4000 Rheumatoid Arthritis treatment vaccine downregulates pro-inflammatory T-cell responses and upregulates anti-inflammatory T-cell responses. This finding was confirmed by an examination of cytokines in the serum of the animals and by earlier data on CEL-4000 and CEL-2000 in the two animal models examined. Information on other autoimmune conditions showing either a Th1 or Th17 signature cytokine profile was cited and supportive as well.

Dr. Zimmerman said, “I believe based on the above findings and observations of others that the future of this novel approach using LEAPS therapeutic vaccines could be expanded to other autoimmune conditions with similar Th1 and Th17 signature cytokine phenotypes including multiple sclerosis, autoimmune uveitis, and type I diabetes.”

About the World Vaccine Congress

The World Vaccine Congress is now well-established as the must attend global vaccine event each year, where leaders of the industry come to discuss science and do business. Now in its 17th year, the event in 2017 will bring over 700 senior vaccine executives to learn, meet and form partnerships. - See more at: http://www.terrapinn.com/conference/world-vaccine-congress-washington/our-Story.stm#sthash.Cjiak553.dpuf

About LEAPS

L.E.A.P.S. (Ligand Epitope Antigen Presentation System) is a CEL-SCI patented platform technology designed to stimulate antigen-specific immune responses in T-cells using synthetic peptides. LEAPS constructs physically link the antigenic peptide with a T-cell binding ligand and are delivered directly to the recipient immune system by injection or mucosal absorption, potentially enhancing T-cell responses to a particular antigen.

About CEL-SCI

CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K and 10-K/A for the year ended September 30, 2016. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170412005106/en/

CEL-SCI Corporation
Gavin de Windt, 703-506-9460
www.cel-sci.com


Latest CVM Messages
Post #: 1
Page:   [1]
All Forums >> [Market Sectors] >> Healthcare and Pharmaceutical Stocks >> CVM $ CEL-Sci $ Next Hotstock on Watch $ https://investorshub.advfn.com/boards/bo Page: [1]
Jump to:





New Messages No New Messages
Hot Topic w/ New Messages Hot Topic w/o New Messages
Locked w/ New Messages Locked w/o New Messages
 Post New Thread
 Reply to Message
 Post New Poll
 Submit Vote
 Delete My Own Post
 Delete My Own Thread
 Rate Posts


Forum Software © ASPPlayground.NET Advanced Edition 2.4.5 Unicode

0.033